Market Place
Sourcing Support
Clirnet teams-up African Medical Associations to transform healthcare education
29 Apr 2024 //
BUSINESSMICRO
Rilzabrutinib LUNA 3 Phase 3 Study Met Primary Endpoint in ITP
23 Apr 2024 //
PRESS RELEASE
Phase 2 results shows rilzabrutinib improved disease activity in urticaria
24 Feb 2024 //
PRESS RELEASE
This drug for blood disorder shows promise in phase 1-2 clinical trial
18 Apr 2022 //
ET HEALTH
Positive Ph1/2 study results of rilzabrutinib peoplewith immune thrombocytopenia
14 Apr 2022 //
PRESS RELEASE
Positive Phase 1/2 study results of rilzabrutinib in immune thrombocytopenia
14 Apr 2022 //
GLOBENEWSWIRE
Sanofi hit by filing delays for key drugs
29 Oct 2021 //
FIERCEBIOTECH
Sanofi Shutters Principia`s San Francisco Labs Days After BTK Failure
15 Sep 2021 //
BIOSPACE
Sanofi`s BTK inhibitor flunks phase 3 autoimmune trial, delivering blow to $3.7B biotech bet
10 Sep 2021 //
FIERCEBIOTECH
Sanofi’s oral BTK inhibitor rilzabrutinib fails Phase III trial
09 Sep 2021 //
PHARMA TIMES
Principia completes enrollment in ph3 trial of BTK inhibitor, rilzabrutinib
25 Nov 2020 //
PHARMABIZ
Patient Enrollment Concluded Early in PEGASUS Ph3 Trial for Rilzabrutinib
24 Nov 2020 //
GLOBENEWSWIRE
US FDA grants fast track designation to BTK inhibitor, rilzabrutinib
18 Nov 2020 //
PHARMABIZ
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.